Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

被引：21

作者：

Takao, Tetsuya ^{[1
]}

Tsujimura, Akira ^{[1
]}

Kiuchi, Hiroshi ^{[1
]}

Matsuoka, Yasuhiro ^{[1
]}

Miyagawa, Yasushi ^{[1
]}

Nonomura, Norio ^{[1
]}

Iwasa, Atsushi ^{[2
]}

Kameoka, Hiroshi ^{[3
]}

Kuroda, Hideya ^{[4
]}

Matsumiya, Kiyomi ^{[5
]}

Uchida, Kinya ^{[6
]}

Yoshimura, Kazuhiro ^{[7
]}

Okuyama, Akihiko ^{[1
]}

机构：

[1] Osaka Univ, Dept Urol, Grad Sch Med, Suita, Osaka 5650871, Japan

[2] Iwasa Clin, Osaka, Japan

[3] Kameoka Clin, Osaka, Japan

[4] Kuroda Clin, Osaka, Japan

[5] Osaka Police Hosp, Dept Urol, Osaka, Japan

[6] Komatsu Hosp, Dept Urol, Osaka, Japan

[7] Toyonaka City Hosp, Dept Urol, Osaka, Japan

来源：

INTERNATIONAL JOURNAL OF UROLOGY | 2008年 / 15卷 / 11期

关键词：

alpha 1-adrenoceptor antagonist; benign prostatic hyperplasia; quality of life; silodosin;

D O I：

10.1111/j.1442-2042.2008.02154.x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: To evaluate the early efficacy of the alpha(1A)-adrenoceptor selective drug, silodosin, for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Methods: A total of 68 patients with an International Prostate Symptom Score (IPSS) of >= 8 and a Quality of Life (QOL) index of >= 2 were included. Changes in the IPSS and QOL index were evaluated before and after 1, 2, 3, 4, 5, 6, 7, 14, and 28 days of twice daily oral administration of 4 mg silodosin. Next, changes in IPSS subscores as well as voiding, storage, and post micturition symptoms were assessed. Changes in total IPSS based on symptom severity were also determined. Results: Total IPSS and QOL index improved significantly from 19.38 +/- 7.46, 4.68 +/- 1.07 at baseline to 15.81 +/- 7.40, 4.22 +/- 1.30 at day 1. The subscores of voiding, storage, and post micturition symptoms were significantly decreased from 8.93 +/- 3.95, 7.97 +/- 3.88, and 2.49 +/- 1.70 at baseline to 7.28 +/- 4.09, 6.52 +/- 3.47, and 2.02 +/- 1.56 at day 1, respectively. This trend continued throughout the study. Regardless of severity, total IPSS were significantly decreased at day 1 and maintained throughout the study. Conclusions: Silodosin may be considered a promising treatment for benign prostatic hyperplasia/lower urinary tract symptom patients.

引用

页码：992 / 996

页数：5

共 31 条

[1]

Andersson KE, 1997, PROSTATE, V30, P202

[2]

[Anonymous], JAPANESE J UROLOGICA

[3] Aua guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations [J].

JOURNAL OF UROLOGY, 2003, 170 (02) :530-547

[4] Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction:: Effect of the α1A and α1D-adrenergic receptor antagonist tamsulosin [J].

Bouchelouche, K ;

Andersen, L ;

Alvarez, S ;

Nordling, J ;

Bouchelouche, P .

JOURNAL OF UROLOGY, 2005, 173 (02) :657-661

[5] Voiding impairment after prostate biopsy:: Does tamsulosin treatment before biopsy decrease this morbidity? [J].

Bozlu, M ;

Ulusoy, E ;

Doruk, E ;

Çayan, S ;

Canpolat, B ;

Schellhammer, PF ;

Akbay, E .

UROLOGY, 2003, 62 (06) :1050-1053

[6] A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing [J].

de Mey, C ;

Michel, MC ;

McEwen, J ;

Moreland, T .

EUROPEAN UROLOGY, 1998, 33 (05) :481-488

[7] A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction [J].

Djavan, B ;

Marberger, M .

EUROPEAN UROLOGY, 1999, 36 (01) :1-12

[8] Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial [J].

Gotoh, M ;

Kamihira, O ;

Kinukawa, T ;

Ono, Y ;

Ohshima, S ;

Origasa, H .

BJU INTERNATIONAL, 2005, 96 (04) :581-586

[9]

Homma Y, 1996, Int J Urol, V3, P267, DOI 10.1111/j.1442-2042.1996.tb00532.x

[10] Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia:: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men [J].

Kawabe, Kazuki ;

Yoshida, Masaki ;

Homma, Yukio .

BJU INTERNATIONAL, 2006, 98 (05) :1019-1024

← 1 2 3 4 →